Our previous studies have demonstrated that nitric oxide (NO) leads to nitric oxide synthase (NOS) uncoupling and an increase in NOS-derived superoxide. However, the cause of this uncoupling has not been adequately resolved. The pteridine cofactor tetrahydrobiopterin (BH 4 ) is a critical determinant of eNOS activity and coupling and GTP cyclohydrolase (GCH I) is the rate-limiting enzyme in its generation. Thus, the initial purpose of this study was to determine whether decreases in BH 4 could underlie, at least in part, the NO-mediated uncoupling of eNOS we have observed both in vitro and in vivo. Initially we evaluated the effect of inhaled NO levels on GCH I expression and BH 4 levels in the intact lamb. Contrary to our hypothesis we found that there was a significant increase in both plasma BH4 levels and peripheral lung GCH I protein levels.
INTRODUCTION
Nitric oxide (NO) is a labile humoral factor synthesized from the oxidation of the guanidinon nitrogen moiety of L-arginine after activation of nitric oxide synthase (NOS) (42) . There are three forms of NOS; constitutive forms are present in endothelial cells (eNOS), neurons (nNOS), and a third, inducible isoform is present in macrophages (iNOS) (4, 32, 62) . Pulmonary vascular endothelial cells synthesize NO after certain stimuli, such as shear stress and the receptor binding of specific vasodilators, activate eNOS (25, 47) . Loss of NO production is the causative factor in the development of various pulmonary hypertensive disorders (6, 16) . Inhaled nitric oxide (NO) is a selective, potent pulmonary vasodilator that is currently used as an adjunct therapy for these pulmonary vasculature diseases (36). However, a number of studies have observed an acute and potentially life-threatening increase in pulmonary vascular resistance (PVR) upon acute withdrawal of inhaled NO. In children with congenital heart disease, this is manifested by an increase in PVR that may compromise cardiac output (2, 39) . While, in newborns with persistent pulmonary hypertension, there is a sudden decrease in systemic arterial oxygen saturation (26). This rebound pulmonary hypertension can occur after hours of therapy and is independent of the initial response; patients with no initial pulmonary vasodilatory response can have life-threatening pulmonary vasoconstriction upon withdrawal. These manifestations of acute NO withdrawal suggests that inhaled NO may alter endogenous endothelial function, although the mechanism is unclear. Both in vitro and in vivo studies have demonstrated that exogenous NO decreases endogenous eNOS activity and increase in the PAECs [8µg]) were separated on 4-20% SDS-polyacrylamide gels, and transferred to PVDF membranes. Immunoblotting was carried out using an antibody raised against GCH I as we have previously described (18) in Tris-base buffered saline with 0.1% Tween20 and 5% BSA. After washing, the membranes were probed with horseradish peroxidase-conjugated goat antiserum to rabbit or mouse. Reactive bands were visualized using chemiluminescence (SuperSignal West Femto; Pierce) on a Kodak 440CF image station (New Haven, CT). Bands were quantified using Kodak ImageStation software, (Kodak 1D 3.6). To normalize for protein loading, all blots were re-probed with β-actin.
Transient transfection and promoter activity analysis
The GTPCH I promoter constructs 613 GTPCH and 313 GTPCH (a kind gift from Dr Gregory Kapatos, Wayne State University, School of Medicine, Detroit, Michigan) have been described previously (23). A 4-bp mutation was introduced into the CREB consensus sequence within 313 GTPCH construct. The sequence TGACGCGA at -89 in the human GTPCH promoter (23) was changed to TGcaacGA by site-directed mutagenesis, as described previously (61). Cells were co-transfected with 1.6 µg of test plasmid and 0.4 µg of β-gal plasmid (as an internal control to normalize for transfection efficiency) on a 10-cm 2 tissue culture plate at 90% confluency with Effectene transfection reagent (Qiagen, Valencia, CA) according to the manufacturer's instructions. Next day, the cells were split onto six-well plates and allowed to adhere for 36 h. The culture medium was then replaced with fresh DMEM containing of SPNONO (0-50 µM) or forskolin (30 µM) or PKA inhibitor H89 (10 μM) or another structurally unrelated PKA inhibitor, for 16-18h. The luciferase activity of 20 µl of protein extract was determined using Luciferase assay system (Promega, Madison, WI) and β-galactosidase of 10 µl of protein extract was determined using β-galactosidase enzyme assay system (Promega, Madison, WI) as a transfection efficency control.
Nuclear extract preparation and electrophoretic mobility shift assays (EMSA) Nuclear extracts were prepared using the NE-PER nuclear extraction kit (Pierce Biotechnology, Rockford, IL) as we have described previously (30, 31) . Electrophortic mobility shift assays (EMSA) were performed using biotinylated double stranded oligonucleotides corresponding to the CREB site at -89 of the GTPCH promoter (23). The single stranded oligonucleotides were biotinylated using Biotin 3´ End DNA Labeling Kit (Pierce Biotechnology, Rockford, IL) to incorporate 1-3 biotinylated ribonucleotides (Biotin-11-UTP) onto the 3´ end of DNA strands using terminal deoxynucleotidyl transferase (TdT) and then annealed to make it double stranded. The sequence of the oligouncleotide is CREB : -102 5' GCG AGG GCC GTG ACG CGA GGC GGG GCC 3' -73 ( IDT technology, Coralville, IA). Binding reactions involved incubating 10 μg of nuclear extract with biotinylated oligonucleotide and 1 μg poly(dI.dC) for 20 minutes at room temperature. The DNA-protein complexes were resolved on a 5% nondenaturing polyacrylamide gel in 1X TBE buffer, then transferred to nylon membrane and biotinylated oligonucleotide was detected using a LightShift® Chemiluminescent EMSA kit (Pierce Biotechnology, Rockford, IL). Competition reactions were done with 50-, 100-fold excess of unlabeled oligonucleotides. Supershift experiments were conducted by incubating nuclear extracts for 2 hours at room temperature with 4 μg of polyclonal antibodies specific to CREB (catalog # sc-186X) and Phospho-CREB (catalog # sc-7978) (Santa Cruz Biotechnology, Santa Cruz, CA) followed by the addition of biotinylated oligonucleotide. The complexes were visualized using an Image station 440 CF (Eastman Kodak).
Measurement of cAMP levels
Cells were serum starved overnight then treated with SPNONO (0-100 µM, 4h). After treatment, the cells were lysed in 0.1 M HCl. Cell debris was then removed by centrifugation (1000 x g, 10 min) and the supernatant was used to determine the cAMP levels using commercially available cAMP EIA kit (Cayman chemical company, Ann
Arbor, MI). cAMP levels were normalized to total protein content.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.01 for Windows (GraphPad Software, San Diego, CA). The mean ± SEM was calculated for all samples and significance was determined either by the unpaired t-test (for 2 groups) and ANOVA (for ≥ 3groups). For the ANOVA analyses Newman-Kuels post-hoc testing was employed. A value of P <0.05 was considered significant.
RESULTS

Effect of exogenous NO on BH 4 levels and GTP cyclohydrolase I protein levels
Initially we determined the effect of inhaled NO (40ppm, 24h) on the plasma levels of BH4. We found that 24h of inhaled NO significantly increased plasma BH 4 levels ( Fig. 1 A) and this was associated with increased protein levels of GCH I ( Fig. 1 B & C) .
Similarly, we found that the NO donor spermine NONOate (SPNONO, 0-100µM, 4h)
induced a dose-dependent increase in GCH I protein levels ( 
Exogenous NO increases COS7 cAMP and phospho-CREB levels
Previous studies have indicated that GCH1 transcription can be stimulated in certain cell types by the second messenger, cAMP (23). Thus, we next determined if exogenous NO increased cAMP levels in COS7 cells. Our data indicate that SPNONO (20-100 µM, 4 h) significantly increased cellular cAMP levels ( Fig. 3 A) . Further, this was associated with a dose-dependent increase in phospho-CREB levels ( Fig. 3 
B & C).
Effect of exogenous NO and cAMP on GTP cyclohydrolase I promoter activity
We next examined the effect of SPNONO (0-50µM) on GCH I transcription using promoter constructs prepared from the human GCH I gene fused upstream of a luciferase reporter (Fig. 4 A) . We found that SPNONO induced a significant increase in luciferase activity when COS7 cells were transfected with construct containing -446 to +167 (613GTPCH) of the human GCH1 promoter (Fig. 4 B) . Similar results were obtained with a truncated promoter construct containing -146 to +167 (313 GTPCH, Fig. 
B)
. Both these constructs contain a CREB response element (CRE) at -102 to -73 (Fig. 4 A) . To determine the role of CREB in the NO-mediated increase in GCH1
promoter activity, we mutated 4bp of the CREB response element of 313 GTPCH from TGACGCGA to TGcaacGA to generate the construct, 313mutGTPCH (Fig. 4 A) . We found that the mutated GCH1 promoter did not respond to SPNONO (Fig. 4 C) . 
Exogenous NO increases binding of CREB to the GTP cyclohydrolase I promoter
We next examined the effect of exogenous NO on CREB binding at to the GCH1
promoter sequence located at -89 (Fig. 6 A) . We performed EMSA using nuclear extracts prepared from COS7 cells to evaluate the effect of SPNONO (0-50µm, 4 h) on CREB DNA binding activity. Compared to untreated extracts, we observed a significant increase in the binding of CREB to the GTPCH I DNA (Fig. 6 A & B) . The CREB complex was competed out with 50x, 100x excess of unlabeled CREB oligonucleotide demonstrating specificity of binding (Fig. 6 C) . The presence of CREB in the DNA binding complex was also confirmed using supershift analysis with antibodies against both CREB and phospho-CREB (Fig. 6 D) . The presence of a higher migrating supershifted band following incubation with anti-CREB and anti-phospho-CREB polyclonal antibodies provides evidence that increased signal in SPNONO treated cells is due to CREB in the binding complex (Fig. 6 D) .
Effect of exogenous NO on GTP cyclohydrolase I regulation in pulmonary arterial endothelial cells
As our in vitro data was carried out in COS7 cells we wanted to verify that these same events occurred in a more physiologically relevant cell culture model. To accomplish this we utilized PAECs isolated from the sheep. Initially, we examined the effect of SPNONO (50µM, 4h) on cellular cAMP levels. We found that SPNONO significantly increased cAMP levels in PAECs (Fig. 7 A) . Next we transfected PAECs with the 313GTPCH and 313mutGTPCH promoter constructs and exposed them to SPNONO (0-50µM, 16-18h). Our data indicate that SPNONO significantly increased GCH I promoter activity in the 313GTPCH construct (Fig. 7 B) while the mutant GTPCH construct did not respond (Fig. 7 C) . Similar to COS7 cells we found that SPNONO also dose-dependently increased GTPCH I protein levels ( Fig. 7 D & E) as well as cellular BH 4 levels ( Fig. 7 E) .
DISCUSSION
In infants and children with congenital heart disease, and patients with acute lung injury inhaled nitric oxide (NO) is used as an adjuvant therapy. It produces potent, selective pulmonary vasodilation that is independent of endothelial cell function. Although many patients benefit from inhaled NO, several problems associated with its use have emerged, including unpredictable or non-sustained responses to therapy, and rapid, even life-threatening, increases in pulmonary vascular resistance (PVR) following its acute withdrawal (2, 11). This "rebound pulmonary" hypertension is one of the most significant safety issues regarding inhaled NO therapy. Sudden increases in pulmonary vascular resistance on acute withdrawal of therapy have been described in patients with a variety of pulmonary vascular disorders (2, 8, 34, 39) .
Our laboratory has previously demonstrated that exogenous NO can reduce eNOS activity in lamb and ovine PAECs, independent of eNOS protein levels (3, 50).
Exogenously added NO or NO-donor compounds inhibit the activity of neuronal NOS in rat cerebellum, endothelial NOS in bovine aortic endothelial cells, and inducible NOS in activated rat alveolar macrophages (5, 17, 44, 45) .These reports have led to the concept of eNOS "uncoupling", characterized by the discrepancy between eNOS protein levels and NO availability. Previously, we have reported in endothelial cells that exogenous addition of NO causes a decrease in eNOS activity but an increase in superoxide levels (50). Similar results were obtained in an in vivo study, where lambs were exposed to inhaled NO for 24 h leading to an increase in superoxide levels and decrease in eNOS activity without any change in eNOS expression (3, 41 level in plasma, despite a decrease in eNOS activity (3). We also observed increased levels of BH 4 in COS7 cells and PAECs exposed to exogenous NO indicating that NOmediated decreases in BH 4 are unlikely to underlie the increased eNOS uncoupling and other mechanisms must be involved. Although these are still unresolved we can speculate. We have previously found both in vitro and in vivo that exogenous NO exposure causes an increase in peroxynitrite production and increased eNOS nitration is involved in eNOS inhibition (60). Recently using liquid chromatography/mass spectrometry we have elucidated the nitration sites on eNOS (64). In this study we have identified four tyrosine residues that can be modified by nitration and are located in the region of eNOS responsible for the binding to heat shock protein 90 (HSP90). The interaction of HSP 90 with eNOS is important as it modulates the relative production of NO and superoxide (43); this interaction is inhibited in hypercholesterolemia and has been shown to cause eNOS uncoupling (43). In addition, limited availability of the substrate L-arginine which may reduce NO synthesis, and thereby increase superoxide production (54) could be involved. However, further studies will be required to test these possibilities.
GTP cyclohydrolase I (GCH I) is the first and the rate-limiting enzyme in BH 4
biosynthesis. In inhaled NO lambs, we have observed an increase in GCH 1 expression. Similar results were observed in COS7 cells treated with NO donor spermine NONOate. Previous studies have shown that GCH I expression is regulated at the transcriptional level. Cytokines and inflammatory mediators such as interferon-γ, interleukin 1β, tumor necrosis factor (TNF) and lipopolysaccharide increase GCH I transcription and enzymatic activity (9, 13, 15, 65) . Studies of the rat and human GCH I promoter have identified the 146 bp upstream from the transcription start site as the minimal sequence necessary for cell type-specific cAMP-dependent transcription (23, 27) . In our study, we also observed an increase in activity of GCH I promoter construct containing 146 bp upstream from the transcription start site with nitric oxide treatment.
This sequence contains a GC-box, a CRE and a CCAAT-box that are evolutionarily In this study, we also observed an increase in cAMP levels both in PAECs and COS7 cells with SPNONO treatment. We also observed an increase in GCH1 promoter activity with forskolin (a rapid activator of adenylate cyclase) treatment and an attenuated response when we mutated the CREB binding site at -89, again supporting the conclusion that cAMP signaling plays a key role in regulating GCH I expression.
It should be noted that our data do not identify the mechanism by which exogenous NO increases cAMP levels. However, there are prior studies that agree with our findings.
For example, it has been reported in porcine PAECs exposed to sepiaptarin exhibited an increase in NO production and enhanced cAMP levels (20). While in vivo increases in NO have been found to cause elevations in cAMP levels (20, 29) and increases in cAMP have been found to increase NO production (21, 63). However, in other studies increases in NO has been shown to decrease cAMP levels. For example, in rat kidney cortical ducts treatment with SPNONO decreased cAMP levels and similar results were observed in U937 cells treated with sodium nitroprusside (SNP) or S-nitroso-Nacetylpenicillamine (SNAP) (14, 35) . While in a study exposing rats to inhaled NO found no change in cAMP levels (24). Together these reports point to conflicting results of NO on cAMP regulation. However, we speculate that the signaling molecule involved in increasing cAMP levels may be cGMP. NO stimulates cGMP synthesis from GTP by binding to the heme prosthetic group of soluble guanylate cyclase. Cyclic GMP (and cAMP) is degraded by the action of specific phosphodiesterases (PDEs). In the lung PDE5 degrades cGMP while cAMP can be degraded by a number of PDEs including PDE2A, PDE3A, and PDE4 (12). Interestingly, in HUVECs cGMP was found to inhibit PDE3A (57) suggesting that exogenous NO could increase cAMP levels via a cGMPmediated inhibition of PDE3A. However, further studies will be required to test this possibility.
In conclusion, our data indicate that NO-mediated decreases in BH 4 levels does not play a major role in the increase in eNOS uncoupling induced by exogenous NO.
appears to involve an NO-mediated increase in cAMP levels that leads to the phosphorylation and activation of CREB. We believe this to be the first report elucidating the mechanism of BH 4 regulation by exogenous NO. Further we speculate that by further characterizing the molecular mechanisms by which GCH I is regulated may identify potential therapies to stimulate BH 4 levels and decrease the endothelial dysfunction associated with eNOS uncoupling that exists in a number of cardiovascular disease states. Panel A: 4-week old lambs were exposed to inhaled NO (40 ppm, 0-24h). Plasma BH 4 levels were then measured using high-performance liquid chromatography. There is increase in plasma BH 4 levels after inhaled NO. Values expressed are mean + SEM, n=4; *p<0.05 vs. pre inhaled NO.
Panel B: Protein extracts (50 µg) prepared from peripheral lung pre-and post-inhaled NO were analyzed using a specific antisera raised against GCH I. GCH I expression was also normalized for loading using β-actin. Values expressed are means + SEM, n=3, *p<0.05 vs. untreated.
Panel F: PAEC were treated with SPNONO (50 µM, 24h) and BH 4 levels were then measured using high-performance liquid chromatography. There is a significant
